Moreau, P., Sonneveld, P., Einsele, H., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antaonioli, E., Leleu, X. P., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Pei, H., Sitthi-Amorn, A., Carson, R. L., Dimopoulos, M. A., Rodriguez-Otero, P., Boccadoro, M. (2025). Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.7501